Safety and effectiveness of sodium–glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitor for patients with heart failure with reduced ejection fraction
Dr. Kanish Bansal
MBBS, MD (Internal Medicine),
PGDDM (UK),
Consultant Physician and Diabetolgist,
Chandigarh
This review examines the effectiveness and safety of angiotensin receptor-neprilysin inhibitor (ARNI) combined with sodium–glucose cotransporter-2 (SGLT2) inhibitors compared to ARNI or SGLT2 inhibitors alone in patients with heart failure with reduced ejection fraction (HFrEF). The meta-analysis found that ARNI combined with SGLT2 inhibitors reduced hospitalization for heart failure or cardiovascular death by 32%, hospitalization for heart failure by 35%, and cardiovascular death by 35%. Additionally, ARNI combined with SGLT2 inhibitors reduced cardiovascular death by 36% and all-cause death by 28% in patients with HFrEF. The study suggests that ARNI combined with SGLT2 inhibitors may be effective and safe for HFrEF patients.
Click Here To View More: